List of Excipients in API sorafenib
Excipients in NDA-approved (novel) drugs containing sorafenib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc | NEXAVAR | sorafenib | 50419-488 | CELLULOSE, MICROCRYSTALLINE | |
| Bayer HealthCare Pharmaceuticals Inc | NEXAVAR | sorafenib | 50419-488 | CROSCARMELLOSE SODIUM | |
| Bayer HealthCare Pharmaceuticals Inc | NEXAVAR | sorafenib | 50419-488 | FERRIC OXIDE RED | |
| Bayer HealthCare Pharmaceuticals Inc | NEXAVAR | sorafenib | 50419-488 | HYPROMELLOSE | |
| Bayer HealthCare Pharmaceuticals Inc | NEXAVAR | sorafenib | 50419-488 | MAGNESIUM STEARATE | |
| Bayer HealthCare Pharmaceuticals Inc | NEXAVAR | sorafenib | 50419-488 | POLYETHYLENE GLYCOL | |
| Bayer HealthCare Pharmaceuticals Inc | NEXAVAR | sorafenib | 50419-488 | SODIUM LAURYL SULFATE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing sorafenib
Detailed excipient profiles for sorafenib
Excipient focus: CARBOXYMETHYLCELLULOSE CALCIUM
sorafenib drug variants containing CARBOXYMETHYLCELLULOSE CALCIUM
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | sorafenib | 0378-1201 |
| >Company | >Ingredient | >NDC |
sorafenib drug variants not containing CARBOXYMETHYLCELLULOSE CALCIUM
Excipient focus: CELLULOSE, MICROCRYSTALLINE
sorafenib drug variants containing CELLULOSE, MICROCRYSTALLINE
sorafenib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | sorafenib | 0378-1201 |
| Teva Pharmaceuticals Inc | sorafenib | 0480-5425 |
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
sorafenib drug variants containing CROSCARMELLOSE SODIUM
sorafenib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals Inc | sorafenib | 0480-5425 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
sorafenib drug variants containing FERRIC OXIDE RED
sorafenib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals Inc | sorafenib | 0480-5425 |
| DrReddys Laboratories Inc | sorafenib | 43598-458 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
sorafenib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | sorafenib | 43598-458 |
| >Company | >Ingredient | >NDC |
sorafenib drug variants not containing FERRIC OXIDE YELLOW
Excipient focus: HYPROMELLOSE
sorafenib drug variants containing HYPROMELLOSE
sorafenib drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | sorafenib | 0378-1201 |
| Teva Pharmaceuticals Inc | sorafenib | 0480-5425 |
| DrReddys Laboratories Inc | sorafenib | 43598-458 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
sorafenib drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | sorafenib | 0378-1201 |
| Teva Pharmaceuticals Inc | sorafenib | 0480-5425 |
| DrReddys Laboratories Inc | sorafenib | 43598-458 |
| >Company | >Ingredient | >NDC |
sorafenib drug variants not containing HYPROMELLOSE 2910
Excipient focus: MAGNESIUM STEARATE
sorafenib drug variants containing MAGNESIUM STEARATE
sorafenib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals Inc | sorafenib | 0480-5425 |
| >Company | >Ingredient | >NDC |
Excipient focus: MICROCRYSTALLINE CELLULOSE 101
sorafenib drug variants containing MICROCRYSTALLINE CELLULOSE 101
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | sorafenib | 0378-1201 |
| >Company | >Ingredient | >NDC |
sorafenib drug variants not containing MICROCRYSTALLINE CELLULOSE 101
Excipient focus: MICROCRYSTALLINE CELLULOSE 102
sorafenib drug variants containing MICROCRYSTALLINE CELLULOSE 102
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals Inc | sorafenib | 0480-5425 |
| >Company | >Ingredient | >NDC |
sorafenib drug variants not containing MICROCRYSTALLINE CELLULOSE 102
Excipient focus: POLYETHYLENE GLYCOL
sorafenib drug variants containing POLYETHYLENE GLYCOL
sorafenib drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | sorafenib | 0378-1201 |
| Teva Pharmaceuticals Inc | sorafenib | 0480-5425 |
| DrReddys Laboratories Inc | sorafenib | 43598-458 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 4000
sorafenib drug variants containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | sorafenib | 0378-1201 |
| >Company | >Ingredient | >NDC |
sorafenib drug variants not containing POLYETHYLENE GLYCOL 4000
Excipient focus: POLYETHYLENE GLYCOL 6000
sorafenib drug variants containing POLYETHYLENE GLYCOL 6000
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | sorafenib | 43598-458 |
| >Company | >Ingredient | >NDC |
sorafenib drug variants not containing POLYETHYLENE GLYCOL 6000
Excipient focus: SODIUM LAURYL SULFATE
sorafenib drug variants containing SODIUM LAURYL SULFATE
sorafenib drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals Inc | sorafenib | 0480-5425 |
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
sorafenib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | sorafenib | 43598-458 |
| >Company | >Ingredient | >NDC |
sorafenib drug variants not containing TALC
Excipient focus: TITANIUM DIOXIDE
sorafenib drug variants containing TITANIUM DIOXIDE
sorafenib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals Inc | sorafenib | 0480-5425 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch